New antibiotic candidate JKN2501 begins first human safety tests
NCT ID NCT07207291
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 38 times
Summary
This early-stage study is testing a new drug called JKN2501 in 66 healthy adults in China. The goal is to see if the drug is safe and how the body processes it, not to treat any disease. Participants will receive either the drug or a placebo by IV, and researchers will monitor for side effects and measure drug levels in blood, urine, and stool.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY TRACT INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third hospital of Changsha
RECRUITINGChangsha, Hunan, 410035, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.